Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + cisplatin + lenvatinib
- Development stage
- Unknown
- Lead developer
- Eisai
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
gemcitabine + cisplatin + lenvatinib is a combination therapy regimen being evaluated for the treatment of advanced or unresectable intrahepatic cholangiocarcinoma. The regimen consists of lenvatinib, an oral multi-kinase inhibitor, combined with the chemotherapy doublet of gemcitabine and cisplatin (GC). Lenvatinib functions by inhibiting multiple receptor tyrosine kinases involved in angiogenesis and tumor growth, including VEGFR1-3, FGFR1-4, PDGFRα, RET, and KIT. Gemcitabine is a nucleoside metabolic inhibitor that disrupts DNA synthesis, while cisplatin is a platinum-based agent that forms DNA cross-links, leading to apoptosis. This specific combination is being investigated in clinical trials led by Shanghai Zhongshan Hospital to improve outcomes in patients with biliary tract cancers.
- Brand names
- Lenvima
- Other names
- GC combined LenvatinibLenvatinib plus GC
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)DNA polymerase familyPDGFRA (Platelet-derived growth factor receptor alpha)RNR (Ribonucleotide reductase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR3 (Fibroblast growth factor receptor 3)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)FGFR2 (Keratinocyte growth factor receptor)
Beyond the preview
Go deeper on gemcitabine + cisplatin + lenvatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + cisplatin + lenvatinib.